James Brugarolas

18.0k total citations · 5 hit papers
194 papers, 10.6k citations indexed

About

James Brugarolas is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, James Brugarolas has authored 194 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Pulmonary and Respiratory Medicine, 118 papers in Molecular Biology and 89 papers in Cancer Research. Recurrent topics in James Brugarolas's work include Renal cell carcinoma treatment (129 papers), Renal and related cancers (73 papers) and Cancer Genomics and Diagnostics (66 papers). James Brugarolas is often cited by papers focused on Renal cell carcinoma treatment (129 papers), Renal and related cancers (73 papers) and Cancer Genomics and Diagnostics (66 papers). James Brugarolas collaborates with scholars based in United States, Canada and United Kingdom. James Brugarolas's co-authors include Tyler Jacks, William G. Kaelin, Samuel Peña‐Llopis, Payal Kapur, Jeffrey I. Gordon, Chitra Chandrasekaran, David Beach, Gregory J. Hannon, William R. Sellers and Alana Christie and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

James Brugarolas

183 papers receiving 10.5k citations

Hit Papers

Regulation of mTOR function in response to hypoxia by RED... 1995 2026 2005 2015 2004 1995 2004 2003 2018 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex
    2004 1.1k citations James Brugarolas et al. profile →
  2. Radiation-induced cell cycle arrest compromised by p21 deficiency
    1995 1.1k citations James Brugarolas et al. profile →
  3. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
    2004 781 citations James Brugarolas et al. profile →
  4. TSC2 regulates VEGF through mTOR-dependent and -independent pathways
    2003 429 citations James Brugarolas et al. profile →
  5. The complex relationship between TFEB transcription factor phosphorylation and subcellular localization
    2018 381 citations Rosa Puertollano, Shawn M. Ferguson et al. The EMBO Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Brugarolas United States 48 6.8k 3.5k 3.2k 2.7k 1.1k 194 10.6k
Jessica Hicks United States 59 4.7k 0.7× 4.7k 1.3× 2.6k 0.8× 2.6k 0.9× 749 0.7× 157 9.7k
Hui‐Kuan Lin United States 53 7.6k 1.1× 1.8k 0.5× 2.4k 0.8× 2.3k 0.8× 1.0k 0.9× 120 10.7k
James J. Hsieh United States 53 8.6k 1.3× 4.5k 1.3× 3.5k 1.1× 2.2k 0.8× 653 0.6× 176 11.8k
Agnieszka K. Witkiewicz United States 60 7.0k 1.0× 3.1k 0.9× 5.1k 1.6× 6.5k 2.4× 1.3k 1.2× 176 13.6k
Maria Tretiakova United States 54 4.5k 0.7× 3.4k 1.0× 2.1k 0.6× 3.0k 1.1× 1.0k 1.0× 177 10.4k
Olivier Kocher United States 46 4.6k 0.7× 3.0k 0.8× 1.7k 0.5× 2.9k 1.0× 683 0.6× 93 9.3k
Luc Girard United States 60 8.1k 1.2× 2.8k 0.8× 3.0k 0.9× 4.5k 1.6× 900 0.8× 168 12.2k
W.K. Alfred Yung United States 64 8.1k 1.2× 2.9k 0.8× 3.2k 1.0× 3.8k 1.4× 1.0k 1.0× 175 15.0k
Jahn M. Nesland Norway 53 5.5k 0.8× 3.0k 0.8× 2.3k 0.7× 4.5k 1.7× 763 0.7× 203 11.4k
Takashi Kohno Japan 66 9.5k 1.4× 4.1k 1.2× 4.4k 1.4× 4.5k 1.7× 857 0.8× 334 14.4k

Countries citing papers authored by James Brugarolas

Since Specialization
Citations

This map shows the geographic impact of James Brugarolas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Brugarolas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Brugarolas more than expected).

Fields of papers citing papers by James Brugarolas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Brugarolas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Brugarolas. The network helps show where James Brugarolas may publish in the future.

Co-authorship network of co-authors of James Brugarolas

This figure shows the co-authorship network connecting the top 25 collaborators of James Brugarolas. A scholar is included among the top collaborators of James Brugarolas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Brugarolas. James Brugarolas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yen, Allen, Shanshan Tang, Alana Christie, et al.. (2025). Predictive Factors for Oligometastatic Renal Cell Carcinoma Treated with Stereotactic Radiation: A Retrospective Study. European Urology Oncology. 8(5). 1237–1247.
2.
Rakheja, Dinesh, et al.. (2025). Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial. Nature Communications. 16(1). 2610–2610. 11 indexed citations
3.
Agarwal, Neeraj, James Brugarolas, Pooja Ghatalia, et al.. (2024). Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Annals of Oncology. 35(12). 1148–1156. 6 indexed citations
4.
Wang, Dazhi, Iqbal Mahmud, Vijay S. Thakur, et al.. (2024). GPR1 and CMKLR1 Control Lipid Metabolism to Support the Development of Clear Cell Renal Cell Carcinoma. Cancer Research. 84(13). 2141–2154. 9 indexed citations
5.
Brugarolas, James, Kathryn E. Beckermann, Brian I. Rini, et al.. (2024). A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 30(11). 2402–2411. 12 indexed citations
6.
Genova, Francesca, Roberta Lucianò, Andrea Raimondi, et al.. (2024). PML restrains p53 activity and cellular senescence in clear cell renal cell carcinoma. EMBO Molecular Medicine. 16(6). 1324–1351. 7 indexed citations
7.
Yang, Juan, Ramesh Butti, Vanina Toffessi Tcheuyap, et al.. (2024). Unconventional mechanism of action and resistance to rapalogs in renal cancer. Proceedings of the National Academy of Sciences. 121(25). e2310793121–e2310793121. 6 indexed citations
8.
Brugarolas, James, Pooja Ghatalia, S. George, et al.. (2023). 1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study. Annals of Oncology. 34. S1011–S1011. 4 indexed citations
9.
Hannan, Raquibul, Mark F. McLaughlin, Laurentiu M. Pop, et al.. (2023). Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer. European Urology. 84(3). 275–286. 27 indexed citations
10.
Rini, Brian I., James Brugarolas, & Michael B. Atkins. (2023). Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 11(3). e006361–e006361. 3 indexed citations
11.
Yin, Jianyi, Roy Elias, Lan Peng, et al.. (2022). Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma. Clinical Genitourinary Cancer. 20(3). 260–269. 16 indexed citations
12.
Lu, Tianshi, Shidan Wang, Lin Xu, et al.. (2020). Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. Science Immunology. 5(44). 30 indexed citations
13.
Patel, Viral, Roy Elias, William Schwartzman, et al.. (2020). Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 8(2). e001198–e001198. 24 indexed citations
14.
Rini, Brian I., E. Jason Abel, Laurence Albigès, et al.. (2020). Summary from the Kidney Cancer Association’s Inaugural Think Thank: Coalition for a Cure. Clinical Genitourinary Cancer. 19(2). 167–175. 3 indexed citations
15.
Yun, Eun-Jin, Andrew Dang, Jiaming Guo, et al.. (2019). Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation. Clinical Cancer Research. 25(14). 4542–4551. 22 indexed citations
16.
Puertollano, Rosa, Shawn M. Ferguson, James Brugarolas, & Andrea Ballabio. (2018). The complex relationship between TFEB transcription factor phosphorylation and subcellular localization. The EMBO Journal. 37(11). 381 indexed citations breakdown →
17.
Ascierto, Paolo A., James Brugarolas, Luigi Buonaguro, et al.. (2018). Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). Journal for ImmunoTherapy of Cancer. 6(1). 69–69. 9 indexed citations
18.
Christie, Alana, Tiffani McKenzie, Nicholas C. Wolff, et al.. (2017). Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. Cancer Discovery. 7(8). 900–917. 110 indexed citations
19.
Schmidt, Laura S., Jessica L. Mester, Samuel Peña‐Llopis, et al.. (2013). A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma. Molecular Cancer Research. 11(9). 1061–1071. 113 indexed citations
20.
Peña‐Llopis, Samuel, Alana Christie, Xian-Jin Xie, & James Brugarolas. (2013). Cooperation and Antagonism among Cancer Genes: The Renal Cancer Paradigm. Cancer Research. 73(14). 4173–4179. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jessica Hicks Breakdown of academic impact, for papers by Hui‐Kuan Lin Breakdown of academic impact, for papers by James J. Hsieh Breakdown of academic impact, for papers by Agnieszka K. Witkiewicz Breakdown of academic impact, for papers by Maria Tretiakova Breakdown of academic impact, for papers by Olivier Kocher Breakdown of academic impact, for papers by Luc Girard Breakdown of academic impact, for papers by W.K. Alfred Yung Breakdown of academic impact, for papers by Jahn M. Nesland Breakdown of academic impact, for papers by Takashi Kohno
Rankless by CCL
2026